| Followers | 36 |
| Posts | 11695 |
| Boards Moderated | 0 |
| Alias Born | 02/26/2016 |
Thursday, November 20, 2025 10:44:09 AM
That's the furthest yet for the goalpost repositioning.
There remains the issue of funding. less than $100M is not nearly enough.
Doc328...
I traded long all the way until I didn't. Only hedge I can claim is exiting at times
during free falls or before peaks. Guilty of reentry too soon, too often.
Still 7.16 is better than 3.50
IGB...
This MB would not exist if opinions were not only legal, but encouraged.
Is Ern's status even material let alone verified? Some seem to think so.
Investor...
I like to think that less than dogmatic is the ultimate winner.
It is the allowance for error which guides my positioning not some mythical $M club.
Samk...
You have a much different definition of 58 world class reputations than seemingly was warranted.
K9...
I never quite Day Traded AVXL, but sometimes used a very short leash.
Good Luck as I do not think the volatility necessary for that strategy
will be a daily event for at least the next Quarter or so. However, 10 X .10 is a dollar
and a dollar is 30% so hope springs eternal. Perhaps AVXL may become an $8 stock again.
There remains the issue of funding. less than $100M is not nearly enough.
Doc328...
I traded long all the way until I didn't. Only hedge I can claim is exiting at times
during free falls or before peaks. Guilty of reentry too soon, too often.
Still 7.16 is better than 3.50
IGB...
This MB would not exist if opinions were not only legal, but encouraged.
Is Ern's status even material let alone verified? Some seem to think so.
Investor...
I like to think that less than dogmatic is the ultimate winner.
It is the allowance for error which guides my positioning not some mythical $M club.
Samk...
You have a much different definition of 58 world class reputations than seemingly was warranted.
K9...
I never quite Day Traded AVXL, but sometimes used a very short leash.
Good Luck as I do not think the volatility necessary for that strategy
will be a daily event for at least the next Quarter or so. However, 10 X .10 is a dollar
and a dollar is 30% so hope springs eternal. Perhaps AVXL may become an $8 stock again.
Recent AVXL News
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/25/2025 09:31:44 PM
